Author: Ken Dropiewski

FDA Issues Emergency Use Authorization for Impella RP as Therapy for COVID-19 Patients with Right Heart Failure

DANVERS, Mass.–(BUSINESS WIRE)–The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Impella RP to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism (PE). Abiomed (NASDAQ: ABMD) manufactures Impella RP. Impella RP is a temporary heart pump that provides circulatory support for […]

BIOTRONIK Awarded Group Purchasing Contract for Coronary Products from Vizient

Contract Offers Increased Savings to More than Half of Nation’s Healthcare Organizations for BIOTRONIK’s Coronary Products Including the Orsiro Drug Eluting Stent LAKE OSWEGO, Ore., June 1, 2020 /PRNewswire/ — BIOTRONIK today announced that it has received a group purchasing contract from Vizient, Inc., the largest, member-driven, healthcare performance improvement company in the United States. […]

ARCA Biopharma Announces $9.4 Million Registered Direct Offering

WESTMINSTER, Colo., June 01, 2020 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that it has entered into a definitive securities purchase agreement with certain institutional and accredited investors to purchase, in […]

Amarin Plans to Increase VASCEPA® (icosapent ethyl) Promotion and Education

Significant Opportunity Seen as Patient Visits Resume to Emphasize VASCEPA as the First and Only Drug Approved for Its Current Cardiovascular Risk Reduction Indication DUBLIN, Ireland and BRIDGEWATER, N.J., June 01, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), today announced that it intends to increase the level and breadth of […]

Resverlogix Plans COVID-19 Clinical Trial Program Launch

Epigenetic BET-inhibition to combat COVID-19 CALGARY, Alberta, June 01, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) is pleased to announce that it is moving forward with a plan to further evaluate apabetalone’s impact on COVID-19 in both a preclinical and clinical setting. A first step will be to […]

BRILINTA Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease

New BRILINTA indication expands treatment to high-risk coronary patients without a history of stroke or heart attack WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s BRILINTA® (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of […]

Foldax Wins 2020 MedTech Breakthrough Award for Cardiovascular Technology Innovation

Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies SALT LAKE CITY–(BUSINESS WIRE)–Foldax® announced today that MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market, has selected its Tria™ LifePolymer™ heart valve technology […]

New Alliance Maps the Way in Electrophysiology

A New Strategic Alliance Between BIOTRONIK, A Leader In Cardiac Rhythm Management, and Acutus Medical, Electrophysiology Innovator, Expected to Offer More Efficient and Effective Diagnosis and Treatment for Arrhythmia Patients CARLSBAD, Calif. and BERLIN, May 20, 2020 /PRNewswire/ — Acutus Medical and BIOTRONIK today announced a new alliance to provide a comprehensive portfolio of electrophysiology, mapping, ablation and […]

Per FDA Guidance, Medtronic Temporarily Modifies Several Cardiopulmonary Product Indications for Longer Duration Use in ECMO Therapy to Address COVID-19

DUBLIN, May 29, 2020 (GLOBE NEWSWIRE) — During this critical time, Medtronic remains committed to our strategy of delivering critical care products ― designed and indicated for Extracorporeal Membrane Oxygenation (ECMO) ― to treat patients around the world. Following guidance issued by the U.S. Food and Drug Administration (FDA) on April 6, […]